



# Diagnostic Value of Mammogram for Breast Cancer Screening in Women With Dense Breast Tissue

Neda Shamsalizadeh<sup>1\*</sup>, Arash Khaki<sup>2</sup>

Breast cancer is the second most prevalent cancer among women in the United States (1). Women at a younger age are more likely to have an aggressive case with a poorer prognosis. In the US, about 33,000 women younger than 45 years old are diagnosed with breast cancer annually. Among this age group, breast cancer is the leading cause for cancer-related deaths. It is predicted that around one in eight women will get breast cancer (2). Women younger than 45 years old account for approximately nine percent of all new cases of breast cancer in the US. In addition, dense breast tissue is more prevalent in younger women. Unlike fatty breast tissue, dense breast tissue absorbs more radiation during mammograms (3,4). Therefore, the accuracy and the diagnostic value of mammograms decrease for breast cancer detection among women with dense breast tissue (3). Dense breast tissue increases the risk for developing breast cancer by 4.7 times (1). Studies showed ultrasound (US) increases the breast cancer detection among women with dense breast tissue (1,5). In women with dense tissue adding US testing increased detection sensitivity as compared to only Mammogram screening (6). Regardless of breast type, density, and history, magnetic resonance imaging (MRI) has the highest, and mammography has the lowest sensitivity for breast cancer detection (7). The predicted total cost of metastatic breast cancer will be US\$ 152.4 in 2030 (8). The cost-effectiveness of breast cancer screening with MRI among younger women with dense breast tissue is controversial. A false negative mammogram leads to a failure in finding breast cancer advancement early enough to prevent incurable stages and therefore a premature death (9). In addition, false positive mammograms can cause anxiety and additional costs for women with no breast cancer (9). A quality-assured mammographic screening program showed about two-thirds of women with breast cancer at the time of screening will remain underdiagnosed or the cancer will not be detected early enough so it progresses to metastatic cancer (9,10). Although only women with breast cancer can benefit from mammogram screenings, many of these women remain

Dr Neda Shamsalizadeh is an Assistant Professor of Nursing at San Diego State University Imperial Valley campus. She has a background in midwifery. She earned her PhD in nursing from State University of New York at Binghamton (Binghamton University). Her primary research focus is reproductive health across lifespan. She has conducted research utilizing both quantitative and qualitative methodologies.



underdiagnosed, and some healthy women will be over diagnosed (9). The question is whether a mammogram is a reliable screening test for breast cancer detection or not, especially among women with dense tissue. Therefore, further research with the focus on avoiding underdiagnosis is needed. Using a mammogram as a screening tool may not be appropriate for all types of breast tissues (9). Breast MRI can be a more reliable test for early detection of breast cancer in women with dense tissue (11,12). Literature lacks evidence regarding the cost effectiveness of MRI screening for breast cancer. Retrospective studies can determine the amount of false negative mammograms. In addition, retrospective studies can compare the diagnostic value of MRI with mammograms especially by identifying what percentage of false negative mammograms will be diagnosed using MRI. It is significant to identify the best breast cancer screening technique as it will help early cancer detection and improve management.

## Ethical Issues

Not applicable.

## Conflict of Interests

The authors have no conflicts of interest to disclose.

## References

1. Thigpen D, Kappler A, Brem R. The Role of Ultrasound in Screening Dense Breasts-A Review of the Literature and Practical Solutions for Implementation. *Diagnostics* (Basel). 2018;8(1):20. Published 2018 Mar 16. doi:10.3390/diagnostics8010020
2. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. *CA Cancer J Clin*. 2022;72(6):524–41.
3. Committee opinion no. 625: management of women with dense breasts diagnosed by mammography [published correction appears in *Obstet Gynecol*. 2016 Jan;127(1):166].

Received 7 December 2022, Accepted 14 January 2023, Available online 17 January 2023

<sup>1</sup>San Diego State University-Imperial Valley, CA, USA. <sup>2</sup>Editor-in-Chief of International Journal of Women's Health and Reproduction Sciences.

\*Corresponding Author: Neda Shamsalizadeh, Email: nshamsalizadeh@sdsu.edu



- Obstet Gynecol. 2015;125(3):750-751. doi:10.1097/01.AOG.0000461763.77781.79
4. Boyd NF. Mammographic density and risk of breast cancer. *Am Soc Clin Oncol Educ B*. 2013;33(1):e57–62.
  5. Chen H, Zhou J, Chen Q, Deng Y. Comparison of the sensitivity of mammography, ultrasound, magnetic resonance imaging and combinations of these imaging modalities for the detection of small ( $\leq 2$  cm) breast cancer. *Medicine (Baltimore)*. 2021;100(26).
  6. Yuan W-H, Hsu H-C, Chen Y-Y, Wu C-H. Supplemental breast cancer-screening ultrasonography in women with dense breasts: a systematic review and meta-analysis. *Br J Cancer*. 2020;123(4):673–88.
  7. Aristokli N, Polycarpou I, Themistocleous SC, Sophocleous D, Mamais I. Comparison of the diagnostic performance of Magnetic Resonance Imaging (MRI), ultrasound and mammography for detection of breast cancer based on tumor type, breast density and patient's history: A review. *Radiography*. 2022;28(3): 848-856. doi: 10.1016/j.radi.2022.01.006
  8. Gogate A, Wheeler SB, Reeder-Hayes KE, et al. Projecting the prevalence and costs of metastatic breast cancer from 2015 through 2030. *JNCI Cancer Spectr*. 2021;5(4):pkab063.
  9. Kuhl CK, Baltzer P. You Get What You Pay For: Breast MRI Screening of Women With Dense Breasts Is Cost-effective. *J Natl Cancer Inst*. 2021;113(11):1439-1441. doi:10.1093/jnci/djab120
  10. Farber R, Houssami N, Wortley S, et al. Impact of Full-Field Digital Mammography Versus Film-Screen Mammography in Population Screening: A Meta-Analysis. *J Natl Cancer Inst*. 2021;113(1):16-26. doi:10.1093/jnci/djaa080
  11. Mann RM, Kuhl CK, Moy L. Contrast-enhanced MRI for breast cancer screening. *J Magn Reson Imaging*. 2019;50(2):377–790.
  12. Kaiser CG, Dietzel M, Vag T, Froelich MF. Cost-effectiveness of MR-mammography vs. conventional mammography in screening patients at intermediate risk of breast cancer - A model-based economic evaluation. *Eur J Radiol*. 2021;136:109355. doi:10.1016/j.ejrad.2020.109355

© 2023 The Author(s); This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.